Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 3;7:14981. doi: 10.1038/s41598-017-14092-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Representative leave-one-subtype-out scores plots. Discrimination plots generated for the prediction of: (a) ‘squamous’ subtype to bladder urothelial carcinoma (BLCA); (b) ‘reactive-like’ subtype to breast adenocarcinoma (BRCA); (c) ‘classical’ subtype to glioblastoma multiforme (GBM); (d) ‘ccB(2)’ subtype to kidney renal clear cell carcinoma (KIRC); (e) ‘PRCC Type 2’ subtype to kidney renal papillary cell carcinoma (KIRP); (f) ‘FAB M5’ subtype to acute myeloid leukemia (LAML); (g) ‘IDHmut-codel’ to lower grade glioma (LGG); (h) ‘proximal proliferative’ to lung adenocarcinoma (LUAD); and (i) ‘ETS-fusion negative’ to prostate adenocarcinoma (PRAD). Correctly predicted samples are indicated by green outline, a red ‘x’ denotes non-classified samples and misclassified samples are indicated by red outline. Axes represent discriminant components, where the second component is used only for visualization purposes. The scores plotted are obtained from the ‘best’-chosen dimensionality reduction space. Subtype assignment information is provided in the Methods and Supplementary Information Note 1. Most subtypes were correctly assigned to the respective cancer type with 95–100% accuracy (see Supplementary Table 4).